ArticleAbdominal radiology (New York)2026
Diagnostic performance of Node-RADS on MRI for a standardized assessment of lymph node metastasis in ovarian cancer.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe Node-RADS score was proposed and provided a standardized, comprehensive assessment of lymph nodes (LNs), accounting for both size and configuration criteria. This study aimed to evaluate the diagnostic performance of the Node-RADS in LN metastasis of ovarian cancer (OC).
methodsFrom December 2018 to April 2023, 81 OC patients who underwent MRI and debulking surgery were included. The likelihood of LN metastasis was assessed by the Node-RADS with MRI. The chi-square test and Fisher's exact test were used to assess the differences in size and configuration between LNs with and without metastasis. The diagnostic performance of Node-RADS and its different criteria for LN metastasis was assessed with receiver operating characteristic (ROC) and area under the curve (AUC).
resultsAmong all Node-RADS evaluation criteria, textural changes had the best performance with a sensitivity of 84.6%, a specificity of 78.7%, and a Youden's index of 0.63. At the LN level, the incidence of LN metastasis with Node-RADS scores 1, 2, 3, 4, and 5 was 3.2%, 4.5%, 13.0%, 85.7%, and 86.7%, respectively. The best performance in assessing LN status was observed at Node-RADS scores > 3, with sensitivity, specificity, and Youden's index of 73.1%, 97.8%, and 0.71, respectively. In addition, at the patient and LN levels, the AUC for Node-RADS assessment of LNs was 0.869 and 0.895, respectively.
conclusionNode-RADS could be an appropriate choice for structured reporting of LN metastasis in OC. The diagnostic performance of LN metastasis in OC at a Node-RADS score > 3 was satisfactory.
Indexed as
Identifiers
40810810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.